articleTop 1% cited
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Arthritis & Rheumatism · 2012 · Vol. 64(4) · pp. 1215–1226
Brad H. Rovin✉(The Ohio State University)Richard FurieKevin Latinis(University of Kansas Medical Center)R. John Looney(University of Rochester)Fernando C. Fervenza(Mayo Clinic)Jorge Sánchez‐Guerrero(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán)Romeo MaciucaDavid ZhangJay GargPaul BrunettaGerald B. Appel(Columbia University)LUNAR Investigator Group
Abstract
Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment. The combination of rituximab with MMF and corticosteroids did not result in any new or unexpected safety signals.
Systemic Lupus Erythematosus ResearchRenal Diseases and GlomerulopathiesT-cell and B-cell ImmunologyRituximabMedicineLupus nephritisInternal medicineGastroenterologyClinical endpointPlaceboNeutropeniaAdverse effectCyclophosphamide
MeSH terms
RituximabAdolescentAdrenal Cortex HormonesAdultAgedDouble-Blind MethodDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsLupus NephritisMaleMiddle AgedMycophenolic AcidTreatment Outcome
Funding
- Genentech
Citations
1,404
FWCI
85.47
field-weighted impact
References
53
Percentile
100%
vs. same field & year
Citations per year
Cited by
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Frontiers in Oncology · 2018 · 356 citations
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Lara D. Veeken · 2017 · 351 citations
The frequency and outcome of lupus nephritis: results from an international inception cohort study
Lara D. Veeken · 2015 · 613 citations
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Annals of the Rheumatic Diseases · 2019 · 1,964 citations
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Kidney International · 2021 · 2,277 citations
References
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Blood · 1994 · 1,936 citations
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Arthritis & Rheumatism · 2006 · 1,631 citations
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
Arthritis & Rheumatism · 2009 · 1,365 citations
Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus
Arthritis & Rheumatism · 1997 · 11,386 citations
Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide
Arthritis & Rheumatism · 2002 · 1,058 citations
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
Lara D. Veeken · 2009 · 352 citations
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Journal of the American Society of Nephrology · 2009 · 1,093 citations
The MOS 36-ltem Short-Form Health Survey (SF-36)
Medical Care · 1992 · 29,431 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.